Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric ...

The FDA has approved the first generic formulation of capecitabine (Xeloda), an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer (mCRC) and ...

In the past 5–10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen change ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of capecitabine, having considered evidence on the nature of gastric cancer and the value placed on the ...

We reported previously (Jan. 3, 2008, issue) 1 that capecitabine and oxaliplatin are as effective as infused fluorouracil and cisplatin, respectively, in patients with previously untreated ...

Systemic adjuvant or neoadjuvant chemotherapy, biologic, and hormone therapies have improved outcomes of patients with early-stage breast cancer. However, a substantial number of patients with ...

Metronomic capecitabine plus AI significantly improved PFS and OS in HR-positive, HER2-negative metastatic breast cancer compared to AI alone. The MECCA trial enrolled 263 patients, with balanced ...

The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and ...

Review the side-effects of Capecitabine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

During the first cycle of capecitabine development, three concomitant drugs were found to affect 5-FU clearance. [5] Paracetamol and morphine increased 5-FU clearance by 26% and 41%, respectively, and ...

Capecitabine (Xeloda, Roche Products) is an orally administered pro-drug of fluorouracil. It is converted to fluorouracil by enzymes that are principally located in the liver and tumour tissue. This ...